CLOSE OBSERVATION OF THE PATIENT IS RECOMMENDED WHEN A BETA BLOCKER IS ADMINISTERED TO PATIENTS RECEIVING CATECHOLAMINE-DEPLETING DRUGS SUCH AS RESERPINE, BECAUSE OF POSSIBLE ADDITIVE EFFECTS AND THE PRODUCTION OF HYPOTENSION AND/OR BRADYCARDIA. LEVOBETAXOLOL IS AN ADRENERGIC BLOCKING AGENT; THEREFORE, CAUTION SHOULD BE EXERCISED IN PATIENTS USING CONCOMITANT ADRENERGIC PSYCHOTROPIC DRUGS. CONCOMMITANT ADMINISTRATION OF OTHER SYSTEMIC BETA BLOCKERS MAY HAVE ADDITIVE EFFECTS.